Ultralife Stock Gains Post Q2 Earnings Despite Y/Y Revenue Dip
ULBI's earnings improve in second-quarter 2026 despite softer revenues, as stronger margins, record backlog and operational gains supported its profitable-growth outlook.
Ultralife Q2 Earnings Call Highlights
Ultralife NASDAQ: ULBI reported second-quarter 2026 revenue of $47.9 million, operating income of $3.4 million and diluted earnings per share of $0.15, as the company cited stronger gross margins, a record backlog and continued investment in product development across its battery and communications businesses.
Ultralife Corporation (ULBI) Q2 2026 Earnings Call Transcript
Ultralife Corporation (ULBI) Q2 2026 Earnings Call Transcript
Zacks Initiates Coverage of Ultralife With Underperform Recommendation
Discover why Zacks rates Ultralife as "Underperform", being the first on Wall Street to initiate coverage on the stock. Explore ULBI's struggles with execution risks, margin pressure and commercialization delays that could delay its earnings recovery.
Ultralife Q1 Earnings Call Highlights
Ultralife NASDAQ: ULBI reported a first-quarter loss for fiscal 2026 as lower sales, production disruptions and higher one-time costs weighed on results, even as management pointed to a record backlog and new product activity as signs of future growth.
Ultralife Corporation (ULBI) Q1 2026 Earnings Call Transcript
Ultralife Corporation (ULBI) Q1 2026 Earnings Call Transcript
Ultralife Corporation (ULBI) Q4 2025 Earnings Call Transcript
Ultralife Corporation (ULBI) Q4 2025 Earnings Call Transcript
Ultralife Corporation (ULBI) Q3 2025 Earnings Call Transcript
Ultralife Corporation ( ULBI ) Q3 2025 Earnings Call November 18, 2025 8:30 AM EST Company Participants Michael Manna - President, CEO & Director Philip A. Fain - CFO, Treasurer & Corporate Secretary Conference Call Participants Jody Burfening - Lippert/Heilshorn & Associates, Inc. Presentation Operator Good day, and thank you for standing by.
Ultralife Corporation (ULBI) Q2 2025 Earnings Call Transcript
Ultralife Corporation (NASDAQ:ULBI ) Q2 2025 Earnings Conference Call August 7, 2025 12:00 PM ET Company Participants Michael E. Manna - President, CEO & Director Philip A.
Ultralife Loses Place On Index, But Is Rebounding Robustly
Ultralife was removed from the FTSE Russell 3000 Microcap Index due to a share price slump, but fundamentals remain strong, and recovery is underway. Recent earnings show robust revenue and EPS growth, boosted by the Electrochem acquisition and improved productivity, supporting a bullish outlook. The valuation remains attractive, with forecasted EPS growth and a one-year price target of $14.12, representing a significant upside from current levels.
Ultralife: Recharging Growth With Smart Acquisitions
Ultralife's revenue has been volatile in the past decade or so, but its recent comeback seems to have more legroom to grow. Through a series of recent acquisitions, the company has diversified its revenue dependence on government contracts and obtained access to a more domestic and overseas customer base. Key financial metrics demonstrate strong cash flow and organic integration of its acquisitions, supporting a positive outlook.
Ultralife Corporation (ULBI) Q1 2025 Earnings Call Transcript
Ultralife Corporation (NASDAQ:ULBI ) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Alex Villalta - Investor Relations Mike Manna - President & Chief Executive Officer Phil Fain - Chief Financial Officer Conference Call Participants Josh Sullivan - The Benchmark Company Justin Mechetti - Sidoti & Company Operator Good day and thank you for standing by. Welcome to the Ultralife Corporation First Quarter 2025 Results.
